Men who undergo radical prostatectomy are often prescribed phosphodiesterase type 5 (PDE5) inhibitors to treat erectile dysfunction (ED) after surgery. However, a team of German scientists recently found an association between PDE5 inhibitor use and biochemical recurrence of prostate cancer in this population.
Archives for March 2015
The Peyronie’s Disease Questionnaire (PDQ) is a self-administered PRO that measures psychosexual consequences and treatment outcomes of PD. This study examined the responsiveness of the PDQ.
On March 3, 2015, the U.S. Food and Drug Administration (FDA) announced that new labeling requirements for FDA-approved testosterone products.
Men with sickle cell disease, a blood disorder, are more likely to develop erectile dysfunction (ED) as a result of “minor” instances of recurrent ischemic priapism (RIP), according to researchers from the Johns Hopkins University.
Physical and personal control problems, which may include sexual issues, are among the “unmet needs” of cancer survivors, according to a new study by American scientists.